Use of Antisense Oligodeoxynucleotides for Inhibiting JC Virus

Progressive multifocal leukoencephalopathy (PML) is a rare, fatal demyelinating disease of the brain caused by the polyomavirus JC (JCV) under immunosuppressive conditions. It is pathologically characterized by progressive damage of white matter of the brain by destroying oligodendrocytes at multiple locations. Clinically, PML symptoms include weakness or paralysis, vision loss, impaired speech, and cognitive deterioration. The prognosis of PML is generally poor. No effective therapy for PML has been established. The current strategies to develop a PML therapy focus on blocking viral infection or inhibiting JCV replication. Antisense oligodeoxynucleotides (ODNs) that can block JCV replication and multiplication have been identified and optimized. Use of the ODNs provide a method of inhibiting JCV replication and thereby provide a treatment for PML.

Potential Commercial Applications: Competitive Advantages:
  • JCV/PML Therapeutics
  • JCV Diagnostics
  • JCV Kits
  • Low cost PML therapeutics
  • Lower cost JCV diagnostics
  • Ease of synthesis

Development Stage:
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


Laura Jaeger (NINDS)  ➽ more inventions...

Avindra Nath (NINDS)  ➽ more inventions...

Eugene Major (NINDS)  ➽ more inventions...

Maria Monaco-Kushner (NINDS)  ➽ more inventions...

Michael Ferenczy (NINDS)  ➽ more inventions...

Intellectual Property:
US Pat: 10,036,020 issued 2018-07-31
US Application No. 61/879,833 filed on 2013-09-19
PCT Application No. PCT/US2014/056655 filed on 2014-09-19

Collaboration Opportunity:

The National Institute of Neurological Disorders and Stroke is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize anti-JCV antisense cocktails. For collaboration opportunities, please contact Susan Ano, Ph.D. at or 301-435-5515.

Licensing Contact:
Olufunmilola (Lola) Olufemi,
Phone: 301-451-3748

OTT Reference No: E-547-2013-0
Updated: Feb 11, 2016